- New approach to cannabidiol solutions for skin care
- First in a family of CBD solutions
- Available in U.S. market
This new product leverages cannabidiol (CBD) along with other synergistic components to enable formulators to provide skin revitalization benefits to their consumers. TEGO® CBD Revitalize will initially be offered in the U.S. market, with plans for availability in other regions later this year.
Unlike CBD-based solutions which rely either on CBD itself or on the natural cocktail of constituents that accompany CBD, TEGO® CBD Revitalize brings together a highly purified CBD with scientifically selected components to offer a claims-focused, tailored solution for the market. In this fashion, brands can enjoy specific and differentiated product claims using CBD, without regulatory-related concerns that can emerge from some constituents found in the extract’s natural cocktail.
“We are excited to launch TEGO® CBD Revitalize and help evolve the CBD beauty market to deliver even better on claims and meet consumer needs,” says Arnoldo Fonseca, global head of the BioActives segment in Evonik’s Care Solutions business line.
Evonik’s SimDerma® technology, which underpins the scientific construction of the product, was first presented at a podium presentation at the 2021 International Federation of Society of Cosmetic Chemists' meeting. This technology enables Evonik scientists to design synergistic blends, where collective benefits outperform those of individual components. Further information about TEGO® CBD Revitalize’s synergistic performance was provided through a poster at the 2021 U.S. Society of Cosmetic Chemists' Annual Meeting in December. Customers can now learn more about and request samples of the material for evaluation.
Formulators attending NYSCC Suppliers' Day are encouraged to visit Evonik’s booth 1301 to learn more.
Additional product information is available at intobeauty.evonik.com.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.56 billion in 2021 with about 5,300 employees.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.